GENOCEA BIOSCIENCES, INC. short interest in 2020
In 2020, GENOCEA BIOSCIENCES, INC.'s disclosed short interest ran from 0.45% of shares outstanding on 15 Jan 2020 to 3.16% on 31 Dec 2020, a change of +2.71 percentage points. The year's high was 5.84% on 30 Sep 2020 and its low 0.32% on 15 Jun 2020, averaging 2.00% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.21 days on 30 Oct 2020. Full history: GENOCEA BIOSCIENCES, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2020 in figures
- Start of year
- 0.45% (15 Jan 2020)
- End of year
- 3.16% (31 Dec 2020)
- Change
- +2.71 pp
- High
- 5.84% (30 Sep 2020)
- Low
- 0.32% (15 Jun 2020)
- Average
- 2.00%
- Highest days to cover
- 8.21 (30 Oct 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 0.45% | 1.00 | |
| 31 Jan 2020 | 0.65% | 1.00 | |
| 14 Feb 2020 | 0.86% | 1.72 | 10-K filed, results (8-K) |
| 28 Feb 2020 | 1.16% | 1.00 | |
| 13 Mar 2020 | 1.25% | 1.00 | |
| 31 Mar 2020 | 0.92% | 1.47 | |
| 15 Apr 2020 | 0.83% | 2.16 | |
| 30 Apr 2020 | 0.47% | 1.00 | 10-Q filed, results (8-K) |
| 15 May 2020 | 0.54% | 1.00 | |
| 29 May 2020 | 0.35% | 1.00 | |
| 15 Jun 2020 | 0.32% | 1.00 | |
| 31 Jul 2020 | 2.40% | 1.00 | 10-Q filed, results (8-K) |
| 30 Sep 2020 | 5.84% | 2.74 | |
| 15 Oct 2020 | 5.61% | 7.38 | |
| 30 Oct 2020 | 3.67% | 8.21 | 10-Q filed, results (8-K) |
| 13 Nov 2020 | 3.13% | 3.33 | |
| 30 Nov 2020 | 3.31% | 7.27 | |
| 15 Dec 2020 | 3.16% | 4.08 | |
| 31 Dec 2020 | 3.16% | 4.48 |
See also: GENOCEA BIOSCIENCES, INC.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.